

NDA 19531/S-013  
NDA 19531/S-016

## SUPPLEMENT APPROVAL

B. Braun Medical Inc.  
Attention: Cindy Katsempris  
Director, Regulatory Affairs  
901 Marcon Blvd.  
Allentown, PA 18109

Dear Ms. Katsempris,

Please refer to your supplemental new drug applications (sNDAs) dated and received on July 19, 2021, and February 22, 2023, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Nutrilipid (lipid injectable emulsion), for intravenous use.

We acknowledge receipt of your major amendment dated December 20, 2021, which extended the goal date for supplement 13 (S-013) by three months.

The “Changes Being Effected” sNDA, S-013, provides for the phytosterol limits determined from the study you completed to address the second item in the Notification of New Postmarketing Requirement letter dated October 3, 2013 and shown below.

- Test for the individual component phytosterol content in all batches of Nutrilipid 20% IV Fat Emulsion, manufactured over a three-year period, using the method developed under PMR-1. Based on these test results, establish limits for each of the individual component phytosterols in NutriLipid 20% IV Fat Emulsion in the product specification.
- Additionally, the Warnings and Precautions section of labeling for the plant-based intravenous lipid emulsions, including Nutrilipid, are being updated:
  - Section 5, WARNINGS and PRECAUTIONS
    - Add Section 5.2 Parenteral Nutrition-Associated Liver Disease and Other Hepatobiliary Disorders based
    - Updated the other subsections to reflect class labeling changes intended to improve clarity

We also refer to our letter dated January 24, 2023, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we have determined should be

included in the labeling for intravenous lipid emulsions (ILEs), including Nutrilipid. This information pertains to the risk of clinical decompensation after rapid infusion of ILEs.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [FDA.gov](http://FDA.gov).<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-*

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

*Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.*<sup>3</sup>

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

### **PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

NDA 19531/S-013

NDA 19531/S-016

Page 4

If you have any questions, call Thao Vu, Safety Regulatory Project Manager, at (240) 402-2690.

Sincerely,

*{See appended electronic signature page}*

Judith A. Racoosin, M.D., M.P.H.  
Deputy Director for Safety  
Division of Hepatology and Nutrition  
Office of Immunology and Inflammation  
Office of New Drugs  
Center for Drug Evaluation and Research

ENCLOSURE:

- Content of Labeling
  - Prescribing Information

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

JUDITH A RACOOSIN  
05/17/2023 10:46:27 AM